Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16301619rdf:typepubmed:Citationlld:pubmed
pubmed-article:16301619lifeskim:mentionsumls-concept:C0079488lld:lifeskim
pubmed-article:16301619lifeskim:mentionsumls-concept:C0004561lld:lifeskim
pubmed-article:16301619lifeskim:mentionsumls-concept:C0079904lld:lifeskim
pubmed-article:16301619lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:16301619lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:16301619lifeskim:mentionsumls-concept:C1515877lld:lifeskim
pubmed-article:16301619lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:16301619lifeskim:mentionsumls-concept:C1523987lld:lifeskim
pubmed-article:16301619pubmed:issue11lld:pubmed
pubmed-article:16301619pubmed:dateCreated2005-11-22lld:pubmed
pubmed-article:16301619pubmed:abstractTextHelicobacter pylori causes various gastroduodenal diseases including gastric MALT lymphoma, but the mechanism underlying H. pylori-induced carcinogenesis is not known. The alternative pathway for NF-kappaB activation, which involves the processing of NF-kappaB2/p100 to p52, has been implicated in lymphocyte survival, attenuated apoptosis, and secondary lymphoid tissue development. In this study, we investigated H. pylori-induced activation of NF-kappaB through the alternative pathway in B lymphocytes. In immunoblot and EMSA, H. pylori induced NF-kappaB2/p100 processing to p52 and subsequent nuclear accumulation in IM-9 (human B cell line) cells and human peripheral blood B cells, but not in AGS (human gastric cancer cell line) cells. The activation of the alternative pathway was LPS-dependent but not cag pathogenicity island-dependent. Alternative pathway activation by H. pylori was associated with attenuated apoptosis. The expression levels of B lymphocyte chemoattractant, EBI-1 ligand chemokine, and stromal cell-derived factor-1alpha mRNAs were up-regulated in cocultured human B cells and in infected human gastric mucosa. In the infected mucosa, NF-kappaB2/p100 and p52 were detected immunohistochemically in the cytoplasm and nuclear compartments of lymphocytes, but not in epithelial cells. In summary, H. pylori activates the alternative NF-kappaB pathway in B lymphocytes. The effects on chemokine production and antiapoptosis mediated by H. pylori-induced processing of NF-kappaB2/p100 to p52 may drive lymphocytes to acquire malignant potential.lld:pubmed
pubmed-article:16301619pubmed:languageenglld:pubmed
pubmed-article:16301619pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16301619pubmed:statusMEDLINElld:pubmed
pubmed-article:16301619pubmed:monthDeclld:pubmed
pubmed-article:16301619pubmed:issn0022-1767lld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:OmataMasaoMlld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:MaedaShinSlld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:OguraKeijiKlld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:HirataYoshihi...lld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:YoshidaHaruhi...lld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:KawabeTakaoTlld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:YanaiAyakoAlld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:ShibataWataru...lld:pubmed
pubmed-article:16301619pubmed:authorpubmed-author:OhmaeTomoyaTlld:pubmed
pubmed-article:16301619pubmed:issnTypePrintlld:pubmed
pubmed-article:16301619pubmed:day1lld:pubmed
pubmed-article:16301619pubmed:volume175lld:pubmed
pubmed-article:16301619pubmed:ownerNLMlld:pubmed
pubmed-article:16301619pubmed:authorsCompleteYlld:pubmed
pubmed-article:16301619pubmed:pagination7162-9lld:pubmed
pubmed-article:16301619pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:meshHeadingpubmed-meshheading:16301619...lld:pubmed
pubmed-article:16301619pubmed:year2005lld:pubmed
pubmed-article:16301619pubmed:articleTitleHelicobacter pylori activates NF-kappaB via the alternative pathway in B lymphocytes.lld:pubmed
pubmed-article:16301619pubmed:affiliationDepartment of Gastroenterology, Graduate School of Medicine, University of Tokyo, Hongo, Tokyo, Japan. tohmae-tky@umin.ac.jplld:pubmed
pubmed-article:16301619pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:53859entrezgene:pubmedpubmed-article:16301619lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16301619lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16301619lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16301619lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16301619lld:pubmed